

Speech Therapy

Adjudication Guideline

Rule Category:
Medical

Ref: No:
2013-MN-0006

Version Control:
Version No. 3.0

Effective Date:
15/05/2023

Revision Date:
31/12/2024

Approved by:
Daman

Responsible:
Medical Standards
& Research

**Related Adjudication
Guidelines:**
N/A

Table of Contents

1.	Abstract	3
	1.1 For Members.....	3
	1.2 For Medical Professionals.....	3
2.	Scope	3
3.	Adjudication Policy.....	4
	3.1 Eligibility / Coverage Criteria.....	4
	3.2 Requirements for Coverage	5
	Documentation Requirements	5
	3.3 Non-Coverage.....	6
	3.4 Payment and Coding Rules	7
4.	Denial codes	7
5.	Appendices.....	8
	5.1 References	8
	5.2 Revision History	8

1. Abstract

1.1 For Members

The term varicose derives from the Latin 'varix', which means twisted. A varicose vein is usually tortuous and dilated. Under normal circumstances, blood collected from superficial venous capillaries is directed upward and inward via one-way valves into superficial veins. Failure of one valve puts pressure on its other surrounding valves and may result in retrograde flow, and hence varicosity, of the entire local superficial venous network.

Varicose veins are more likely to happen with pregnancy, age, overweight, standing lots, family history or underlying disease.

Symptoms associated with varicose veins of the lower extremities include pain, cramping, aching, burning, throbbing, swelling and the feeling of heaviness or fatigue in the leg. Management can be required for symptomatic varicose veins.

Daman covers the management of varicose veins, if medically justified as per the best international medical practice and as per the policy terms and conditions of each Health Insurance Plan administered by Daman.

1.2 For Medical Professionals

The varicosity may vary in size from 3–10 mm on average (less than 4 mm is asymptomatic and considered to be cosmetic).

Management of symptomatic varicose veins as per medical necessity is covered for all health insurance plans administered by Daman as per the policy terms and conditions.

Daman does not cover any of the asymptomatic diagnoses of varicose veins and any of the un-proven procedures (listed below in this AR) for varicose veins management due to lack of sufficient evidence to conclude the benefits and efficacy of these procedures.

2. Scope

This guideline aims to specify the coverage details for the management of symptomatic varicose veins for all health insurance plans administered by Daman.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Treatment Modalities

- Conservative Management:
 - Lifestyle modifications e.g. weight loss, avoidance of standing for long periods of time
 - Exercise
 - Elevation of affected legs
 - Support stockings/ compression stockings/ intermittent pneumatic compression devices
 - Drugs

- Surgical Management:
 - Ambulatory phlebectomy
 - Ligation and excision (contra-indicated in deep venous occlusions and infected ulcers)
 - Endoluminal Radiofrequency Ablation (RFA) for great saphenous vein
 - Endo venous-Laser Therapy (EVLT) for great saphenous vein
 - Sclerotherapy (liquid, foam, ultrasound- guided, or endovenous chemical ablation)
 - Subfascial endoscopic perforator surgery

Management of symptomatic varicose veins is covered for all health insurance plans administered by Daman except for the Visitor's Plan which is subject to policy terms and conditions.

Coverage of Doppler ultrasound is limited to one scan prior to the procedure and intra-operative ultrasonic guidance when medically necessary to improve outcomes and minimise complications.

Surgical management of varicose veins will be covered only when the following criteria are met:

1. **Incompetence** at the sapheno-femoral junction or sapheno-popliteal junction is documented by Doppler or duplex ultrasound scanning (not older more than 12 months) along with the findings given below:
 - **Duration of reflux** ≥ 500 milliseconds (ms) in great, small or principal branches of saphenous veins or ≥ 350 ms in perforated veins; *and*

- **Size of vein** \geq 5.5 mm in transverse diameter in great saphenous vein(not valve diameter at junction) or \geq 5 mm in small saphenous vein and principal branches;
and

2. **Saphenous varicosities** resulting in ANY of the following:

- Leg ulceration(s) due to saphenous vein insufficiency refractory to conservative management (ulcerated varicose veins can be accepted irrespective of size and duration of reflux)
- Recurrent bleeding from the saphenous vein or other varicosity (bleeding varicose veins can be accepted irrespective of size and duration of reflux)
- Pain resulting in a clinically significant functional impairment (e.g. inability to perform household chores or prolonged standing, interference with essential job functions)
- Recurrent phlebitis or thrombophlebitis
- Refractory dependent edema
- Persistent stasis dermatitis
- Chronic cellulitis

3.2 Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.

Documentation Requirements

Procedure	Documentation
Ambulatory phlebectomy	Doppler ultrasound information as mentioned above
Radiofrequency Ablation (RFA)	
Endovenous-Laser Therapy (EVL) for GSV, Sub-fascial endoscopic perforator surgery	
Sclerotherapy (liquid, foam, ultrasound-guided, or endovenous chemical ablation)	
Ligation and excision	H/O persistent symptoms despite a 3-month trial of conservative management

<p>Sub-fascial endoscopic perforator surgery (contraindicated in deep venous occlusions and infected ulcers)</p>	<p>Any ONE of the following conditions: Venous stasis dermatitis/ulceration Chronic venous insufficiency</p> <p>H/O persistent symptoms despite a 3-month trial of conservative management</p>
--	--

*Note: A trial of conservative management is not required for persons with persistent or recurrent varicosities who already have undergone the surgical procedures given above in the same leg as post- surgical conservative management is unlikely to be successful.

3.3 Non-Coverage

Daman considers the following diagnoses to be cosmetic, and any services related to these diagnoses will not be covered for any health insurance plan administered by Daman:

- Hereditary haemorrhagic telangiectasia
- Nevus non-neoplastic
- Asymptomatic varicose veins
- Varicose veins developed during pregnancy

Daman does not cover the following procedures for any health insurance plan as there is no sufficient evidence to conclude the benefits and efficacy of these procedures:

- Trans-illuminated Powered Phlebectomy (TIPP).
- Endoluminal Radiofrequency Ablation (ERFA) and Endovenous Laser Therapy (EVLT), if to be done for accessory or perforator veins.
- Endomechanical or mechano-chemical ablative approach (e.g. ClariVein™ Catheter).
- Ligation and excision in deep venous occlusions and infected ulcers as being contraindicated.

***Notes:**

Varicose veins may develop during pregnancy, although surgery or sclerotherapy is not typically performed, as the treatment is not medically necessary. Most varicosities will spontaneously resolve within 4–6 months after delivery.

3.4 Payment and Coding Rules

Please apply regulator payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

4. Denial codes

Code	Code Description
NCOV-001	Diagnosis(es) is (are) not covered
NCOV-003	Service(s) is (are) not covered
MNEC-003	Service is not clinically indicated based on good clinical practice
PRCE-002	Payment is included in the allowance for another service

5. Appendices

5.1 References

- <https://www.hopkinsmedicine.org/health/conditions-and-diseases/varicose-veins>
- <https://www.mayoclinic.org/diseases-conditions/varicose-veins/diagnosis-treatment/drc-20350649>
- <https://www.aad.org/public/cosmetic/younger-looking/how-dermatologists-treat-leg-veins>
- <https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/endovenous-laser-varicose-vein-surgery>
- <https://www.uptodate.com/contents/approach-to-treating-symptomatic-superficial-venous-insufficiency>

5.2 Revision History

Date	Change(s)
01/07/2013	V1.0 <ul style="list-style-type: none"> • Released
15/07/2014	V2.0 <ul style="list-style-type: none"> • New template
31/12/2024	V3.0 <ul style="list-style-type: none"> • New template • Content update • References updated

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.